Claris Lifesciences underwent an audit by the USFDA for pharmacovigilance in the last week of May and has not received any observation.

“Claris Lifesciences along with its wholly-owned subsidiary Claris Injectables Ltd announced today that it underwent a successful USFDA Pharmacovigilance (PV) audit from May 29-31 with no observation (i483s),” the company said in a BSE filing today.

The company shares were trading up by 4.34 per cent at Rs 341.25 on the BSE.

comment COMMENT NOW